메뉴 건너뛰기




Volumn 28, Issue 6, 2009, Pages 706-707

Persistent corneal epithelial defect associated with erlotinib treatment

Author keywords

Corneal erosion; Epidermal growth factor receptor inhibitor; Erlotinib; Infectious keratitis

Indexed keywords

ERLOTINIB; GATIFLOXACIN; HOMATROPINE; LEVOFLOXACIN; PREDNISOLONE ACETATE; VANCOMYCIN;

EID: 67650602962     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31818fdbc6     Document Type: Article
Times cited : (60)

References (6)
  • 2
    • 34547668744 scopus 로고    scopus 로고
    • Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors
    • Zhang G, Basti S, Jampol LM. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors. Cornea. 2007;26:858-860.
    • (2007) Cornea , vol.26 , pp. 858-860
    • Zhang, G.1    Basti, S.2    Jampol, L.M.3
  • 4
    • 0034780526 scopus 로고    scopus 로고
    • The epidermal growth factor receptor (EGFR): Role in corneal wound healing and homeostasis
    • Nakamura Y, Sotozono C, Kinoshita S. The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res. 2001;72:511-517.
    • (2001) Exp Eye Res , vol.72 , pp. 511-517
    • Nakamura, Y.1    Sotozono, C.2    Kinoshita, S.3
  • 5
    • 22744451123 scopus 로고    scopus 로고
    • Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ("Iressa", ZD1839) in phase I and II clinical trials
    • Tullo AB, Esmaeli B, Murray PI, et al. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ("Iressa", ZD1839) in phase I and II clinical trials. Eye. 2005;19:729-738.
    • (2005) Eye , vol.19 , pp. 729-738
    • Tullo, A.B.1    Esmaeli, B.2    Murray, P.I.3
  • 6
    • 48249086178 scopus 로고    scopus 로고
    • Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody)
    • Foerster CG, Cursiefen C, Kruse FE. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea. 2008;27:612-614.
    • (2008) Cornea , vol.27 , pp. 612-614
    • Foerster, C.G.1    Cursiefen, C.2    Kruse, F.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.